Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (461)	2/28/2001 10:23:07 AM
From: tuck	Read Replies (1) \| Respond to of 1784

Wilder, I agree that spinouts tend to benefit the spinner at the expense of the spinnee's shareholders. Genzyme. Need I say more? So I wasn't planning on running out and buying APBI right away. If it gets silly cheap, it might be worth a try. Thanks for your thoughts. Meanwhile, Trickle holding Invitrogen has beaten numbers by 3 cents excluding merger costs. It has been fairly strong recently, and is selling off only a bit on the news: biz.yahoo.com Cheers, Tuck